You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

285 Results
Drug
Other Name(s): Unituxin®
Jun 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Jun 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
Jun 2023
Drug
Other Name(s): Lynparza®
Jan 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jan 2025
Guidelines and Advice
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Jan 2025

Pages